Exosens Stocks

$ 63.9Last Updated 27.04.2026

Issuer Rating

4/7
Performance

Average

Risk

Limited

Recommendation

Hold

Market Cap

$ 3.81B

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 63.9
Key Takeaways

Risk factor

Strong & resilient to price shocks

Data is available to registered users only
Data is available to registered users only

Profitability factor

Strong growth

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Exosens engages in the development, manufacture, and sale of electro-optical technologies in the fields of amplification, and detection and imaging in France, rest of Europe, North America, Asia, Oceania, Africa, and internationally. It offers image intensifier tubes; ultra violet, short and long wave infrared, visible - near infrared, and mid wave infrared cameras, as well as enhanced vision equipment; ion and electron, scintillation, and single photon detection products; x-ray components, neutronic imaging products, and image intensifiers for scientific applications; and gamma and neutron detectors, and mineral insulated extensions. The company also provides power tubes and microwave devices; and methane airborne detection solutions. It operates under the Photonis, Xenics, Telops, and El-Mul brand names. The company serves defense and surveillance, industrial research and control, life science and environment, and nuclear markets. The company was founded in 1937 and is based in Mérignac, France. Exosens operates as a subsidiary of HLD Europe S.C.A.

Company Valuation

Greatly overvalued
1/7

Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EB

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Neutral
4/7
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks